European Business
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
European Business
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
European Business
No Result
View All Result
Home < INDUSTRIES Health

Vividion Therapeutics names Aleksandra Rizo as President and Head of Research and Development

by Marie Weil
June 24, 2022
A A
Dr. Aleksandra Rizo

Dr. Aleksandra Rizo

Share on LinkedinShare on Twitter

Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, and a wholly owned and independently operated subsidiary of Bayer AG, today announced that Aleksandra Rizo, M.D., Ph.D., will join the company as President and Head of Research and Development. Dr. Rizo brings extensive industry leadership experience to Vividion, having held multiple senior executive roles during her career at both biotechnology and large pharmaceutical companies.

“Aleksandra brings proven executive leadership skills, deep translational and clinical development expertise, and the ability to succeed in both large and small company cultures,” said Jeffrey Hatfield, chief executive officer of Vividion. “Her addition to our team comes at an exciting inflection point for our growth, as we clearly see the potential to advance multiple programs into the clinic starting next year.”

“I am very excited to join Vividion to continue to advance innovation in an entrepreneurial environment focused on patient benefits and outcomes,” said Dr. Rizo. “I’m impressed by the pipeline’s breadth of novel, first-in-class programs in oncology and immunology. These programs are nearly all targeting proteins the industry has previously viewed as undruggable and indicate the potential to deliver enormous value to patients if successful. I am also intrigued by the innovative business model established with Bayer that allows us to operate largely autonomously and independently but with the technical expertise and financial stability of a major pharmaceutical company.”

Dr. Rizo has served most recently as Executive Vice President and Chief Medical Officer of Geron Corporation since January 2019 where she provided leadership and direction for all clinical and translational efforts. Included in her reporting responsibilities were clinical development, clinical operations, clinical pharmacology, biometrics, translational research, program management and medical affairs. Prior to joining Geron, Dr. Rizo was Executive Director, Strategy and Clinical Lead, at Celgene Corporation from March 2018 to January 2019, where she led submission activities and participated in strategic development activities in the Myeloid Therapeutic Area. From October 2008 to March 2018, Dr. Rizo served in a number of oncology drug development functions with increasing responsibilities at Janssen Research and Development, LLC (Janssen), including Senior Director, Compound Development Team Leader for all myeloid assets, Senior Director, Global Clinical Leader for the imetelstat, ibrutinib mantle cell lymphoma (MCL) program, and others. In these roles, she had oversight and leadership responsibilities for overall clinical development strategy, study designs, execution and data interpretation. In addition, Dr. Rizo was a core member of Janssen’s Hematology Strategy Team where she participated and led multiple diligence projects in hematology. During her initial tenure with Janssen, Dr. Rizo also worked on Velcade clinical trials in lymphoma and multiple myeloma. Dr. Rizo holds an M.D. from the University Ss Cyril and Methodius, Skopje, Macedonia, where she also completed a residency in internal medicine/hematology. She also has a Ph.D. in human leukemic stem cell biology from the University of Groningen, Groningen, Netherlands, and a Ph.D. in mouse stem cell biology from the University of Tokyo, Tokyo, Japan.

Tags: < PEOPLE

Related Industries

Health

Siemens Healthineers presents mammography system with groundbreaking new imaging technology

September 28, 2023
Health

Dr. Jost Reinhard appointed new head of Investor Relations at Bayer

September 20, 2023
Health

Sandoz completes acquisition of leading antifungal agent Mycamine® from Astellas, reinforcing leading global anti-infectives portfolio

August 29, 2023
Health

Bayer appoints Dr. Juergen Eckhardt as new Head of Pharmaceuticals Business Development & Licensing / Open Innovation

August 23, 2023
Health

Innovative research for malaria control driven by three collaborating parties: Swiss TPH, BASF and Promega

August 18, 2023
Health

SSM Health, Siemens Healthineers partner to advance health equity and empower workforce development in underserved communities

August 15, 2023

ABN AMRO intends to appoint Ton van Nimwegen as COO and member of the Executive Board

September 22, 2023

...

Bayer to invest EUR 220 million in new R&D facility at its Monheim site

September 1, 2023

...

Talking not Typing: Continental and Google Cloud Equip Cars with Generative Artificial Intelligence IAA MOBILITY 2023

September 5, 2023

...

Safran and Cuberg announce collaboration agreement on battery systems for advanced electric aviation

September 14, 2023

...

Getting heavy-duty vehicles in gear for net-zero

September 5, 2023

...

BT and Johnson Controls collaborate to help businesses reach Net Zero faster

September 14, 2023

...

Bringing the power of Dow innovation to Labelexpo Europe 2023

September 6, 2023

...

BYD Brings eTruck Innovation to The Netherlands

September 21, 2023

...

SKF appoints Sophie Arnius as Head of Investor Relations

September 1, 2023

...

Aramco and Stellantis collaboration indicates eFuel compatibility with European engine families

September 6, 2023

...

Asia Pacific Business Asia Pacific Business Asia Pacific Business

EUROPEAN BUSINESS is a premier source of corporate news, business information and insights across broad spectrum of industries in Europe and worldwide.  We are one of the members of the Business World Network.

RESOURCES

  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

CONTACT US

EDITORIAL:     editor # european-biz.com

PARTNERSHIP:     partnership # european-biz.com

HUMAN RESOURCE:     hr # european-biz.com

* (replace # with @)

  • Official Site

Copyright © EUROPEAN-BIZ.COM All rights reserved.

No Result
View All Result
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

Copyright © EUROPEAN-BIZ.COM All rights reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist